Blog


Tofacitinib is a new JAK inhibitor taken by mouth 10mg twice daily. Recent trials (OCTAVE) have shown significant benefit in patients with moderately active UC. The patients had previous failure or intolerance to conventional treatments. Patients receiving tofacitinib were significantly more likely to have a clinical response, healing of the colon or achieve remission than those given placebo tablets at weeks 2, 4 and 8. While this drug has been around some time, this is the latest and largest trial that has produced promising results. It is hoped that it will be licensed and made available for appropriate or selected patients towards the end of 2017.



At West Kent Gastroenterology, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at West Kent Gastroenterology we are continuously making improvements to our services, ensuring the highest level of care possible.

Clinic Locations

Nuffield Hospital
Kingswood Road, Tunbridge Wells, TN2 4UL

Spire Hospital
Fordcombe Road, Tunbridge Wells, Kent, TN3 0RD

Sevenoaks Medical Centre
London Road, Sevenoaks, Kent, TN13 2JD

Twitter

@dradamharris - 7 days

Eosinophilic oesophagits (EoE) is getting more common; the reasons for this are unclear. There is an inverse relati…

@dradamharris - 1 week

Thanks Jonny, Miles's excellent talk is summarised here:

© 2019 West Kent Gastroenterology Ltd.

Designed and Developed By